Aims and Scope
Expert Opinion on Emerging Drugs is a quarterly peer-reviewed medical journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas. Each review includes an "expert opinion" section, in which authors are asked to provide their personal view on the current status and future direction of the research discussed. It was established as Emerging Drugs in 1996, changing to its current name in 2001. It is published by Informa. According to the Journal Citation Reports, the journal has a 2014 impact factor of 3.058. Less
Key Metrics
Journal Specifications
- PublisherTAYLOR & FRANCIS LTD
- LanguageEnglish
- FrequencyQuarterly
- LanguageEnglish
- FrequencyQuarterly
- Publication Start Year2001
- Publisher URL
- Website URL
Ready to spotlight your research findings?
Impress peers and journals alike with a concise, visual summary of your work.
Months | % Papers published |
---|---|
0-3 | 43% |
4-6 | 54% |
7-9 | 3% |
>9 | 0% |
Topics Covered
Year-wise Publication
- 5Y
- 10Y
FAQs
Since when has Expert Opinion on Emerging Drugs been publishing? 
The Expert Opinion on Emerging Drugs has been publishing since 2001 till date.
How frequently is the Expert Opinion on Emerging Drugs published? 
Expert Opinion on Emerging Drugs is published Quarterly.
What is the H-index. SNIP score, Citescore and SJR of Expert Opinion on Emerging Drugs? 
Expert Opinion on Emerging Drugs has a H-index score of 52, Citescore of 5.6, SNIP score of 0.8, & SJR of Q1
Who is the publisher of Expert Opinion on Emerging Drugs? 
The publisher of Expert Opinion on Emerging Drugs is TAYLOR & FRANCIS LTD.
Where can I find a journal's aims and scope of Expert Opinion on Emerging Drugs? 
For the Expert Opinion on Emerging Drugs's Aims and Scope, please refer to the section above on the page.
How can I view the journal metrics of Expert Opinion on Emerging Drugs on editage? 
For the Expert Opinion on Emerging Drugs metrics, please refer to the section above on the page.
What is the eISSN and pISSN number of Expert Opinion on Emerging Drugs? 
The eISSN number is 1744-7623 and pISSN number is 1472-8214 for Expert Opinion on Emerging Drugs.
What is the focus of this journal? 
The journal covers a wide range of topics inlcuding Immune checkpoint inhibitors, Epidermolysis bullosa, Tumor microenvironment, Major depressive disorder, Synthetic drugs, Cirrhosis, Chronic myelomonocytic leukemia, Adrenocortical carcinoma, Cytotoxic chemotherapy, Standard of care, Antibody therapy, Nonalcoholic fatty liver disease, Imatinib, Sunitinib, Treatment options, Regorafenib, Immunotherapy.
Why is it important to find the right journal for my research? 
Choosing the right journal ensures that your research reaches the most relevant audience, thereby maximizing its scholarly impact and contribution to the field.
Can the choice of journal affect my academic career? 
Absolutely. Publishing in reputable journals can enhance your academic profile, making you more competitive for grants, tenure, and other professional opportunities.
Is it advisable to target high-impact journals only? 
While high-impact journals offer greater visibility, they are often highly competitive. It's essential to balance the journal's impact factor with the likelihood of your work being accepted.